Int J Infect Dis . Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition

[tetano]

Int J Infect Dis


. 2020 Aug 20;S1201-9712(20)30677-9.
doi: 10.1016/j.ijid.2020.08.047. Online ahead of print.
Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition


Hidenori Takahashi[SUP] 1 [/SUP], Yoshinobu Iwasaki[SUP] 2 [/SUP], Takayasu Watanabe[SUP] 2 [/SUP], Naoki Ichinose[SUP] 3 [/SUP], Yasusei Okada[SUP] 4 [/SUP], Akito Oiwa[SUP] 5 [/SUP], Takehiro Kobayashi[SUP] 5 [/SUP], Mariko Moriya[SUP] 5 [/SUP], Toshimi Oda[SUP] 3 [/SUP]



Affiliations

• PMID: 32829044
• DOI: 10.1016/j.ijid.2020.08.047

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two of whom were in a critical condition and one of whom was in a severe condition, who were administered favipiravir for their deteriorating conditions and cured.

Keywords: COVID-19; SARS-CoV-2; acute respiratory distress syndrome; favipiravir; viral pneumonia.